The industry’s focus on living human beings and the strict regulations that it imposes are unique to business leaders. These features make the industry an ideal incubator for innovation. They have resulted in major breakthroughs biofuels, agricultural yields and life-saving pharmaceuticals.
When it comes to strategies that generate revenue, biotech start-ups have many options. The majority choose either a technology partnership or an asset creation-and-out-licensing strategy. Technology partnering offers faster revenue with lower risk to the financials, while out-licensing and asset creation strategy generates significantly higher returns when it’s successful. A growing number of biotechs at the research phase employ the hybrid approach, which combines these two approaches.
Those who opt for an approach that is focused on product development can achieve commercial success when they are able to get their pipeline up to the right stage and attract a large pharmaceutical partner or investor with deep pockets. It can be a costly proposition however, and making sure that you balance opportunistic methods to leverage outside resources while making the right scientific decision-making about projects that are homegrown is essential.
The “platform” model is a different option to https://genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/ generate revenue. It is less expensive than product-oriented research, but involves significant risk. In this model biotechs own and develops its platform technology prior to joining with major pharma companies to create a portfolio of drug discovery projects that target specific disease areas (i.e. disease the x gene within biology y). Advinus Therapeutics, among others have embraced this model.